Free Trial
→ Before you buy SpaceX shares, consider this alternative approach (From Weiss Ratings) (Ad)tc pixel Free CMRA Stock Alerts

Comera Life Sciences (CMRA) Competitors

Comera Life Sciences logo
Compare

CMRA vs. ARDS, TRVN, ADTX, NAVB, and PXMD

Should you buy Comera Life Sciences stock or one of its competitors? MarketBeat compares Comera Life Sciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Comera Life Sciences include Aridis Pharmaceuticals (ARDS), Trevena (TRVN), Aditxt (ADTX), Navidea Biopharmaceuticals (NAVB), and PaxMedica (PXMD). These companies are all part of the "pharmaceutical products" industry.

How does Comera Life Sciences compare to Aridis Pharmaceuticals?

Comera Life Sciences (NASDAQ:CMRA) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, earnings and media sentiment.

Comera Life Sciences has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market. Comparatively, Aridis Pharmaceuticals has a beta of 44.97, suggesting that its share price is 4,397% more volatile than the broader market.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Aridis Pharmaceuticals Neutral

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Aridis Pharmaceuticals N/A N/A N/A

9.6% of Aridis Pharmaceuticals shares are owned by institutional investors. 8.9% of Comera Life Sciences shares are owned by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Comera Life Sciences has higher revenue and earnings than Aridis Pharmaceuticals. Comera Life Sciences is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A
Aridis PharmaceuticalsN/AN/A-$30.37M$0.090.00

Summary

Aridis Pharmaceuticals beats Comera Life Sciences on 4 of the 7 factors compared between the two stocks.

How does Comera Life Sciences compare to Trevena?

Trevena (NASDAQ:TRVN) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Company Net Margins Return on Equity Return on Assets
TrevenaN/A N/A -119.55%
Comera Life Sciences N/A N/A N/A

Trevena has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

13.6% of Trevena shares are owned by institutional investors. 2.7% of Trevena shares are owned by insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Comera Life Sciences has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Trevena$443K0.00-$40.29M-$47.04N/A
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A

In the previous week, Trevena's average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
Trevena Neutral
Comera Life Sciences Neutral

Summary

Comera Life Sciences beats Trevena on 6 of the 8 factors compared between the two stocks.

How does Comera Life Sciences compare to Aditxt?

Aditxt (NASDAQ:ADTX) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

Comera Life Sciences has a net margin of 0.00% compared to Aditxt's net margin of -360,152.50%. Comera Life Sciences' return on equity of 0.00% beat Aditxt's return on equity.

Company Net Margins Return on Equity Return on Assets
Aditxt-360,152.50% -374.60% -105.93%
Comera Life Sciences N/A N/A N/A

Comera Life Sciences has higher revenue and earnings than Aditxt. Aditxt is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AditxtN/AN/A-$41.71M-$100.79 thousandN/A
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A

Aditxt has a beta of 0.84, indicating that its share price is 16% less volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

Given Comera Life Sciences' higher possible upside, analysts clearly believe Comera Life Sciences is more favorable than Aditxt.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aditxt
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Comera Life Sciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

15.5% of Aditxt shares are held by institutional investors. 0.0% of Aditxt shares are held by insiders. Comparatively, 8.9% of Comera Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Aditxt had 8 more articles in the media than Comera Life Sciences. MarketBeat recorded 8 mentions for Aditxt and 0 mentions for Comera Life Sciences. Aditxt's average media sentiment score of 0.72 beat Comera Life Sciences' score of 0.00 indicating that Aditxt is being referred to more favorably in the media.

Company Overall Sentiment
Aditxt Positive
Comera Life Sciences Neutral

Summary

Comera Life Sciences beats Aditxt on 9 of the 14 factors compared between the two stocks.

How does Comera Life Sciences compare to Navidea Biopharmaceuticals?

Comera Life Sciences (NASDAQ:CMRA) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, institutional ownership, media sentiment, dividends, risk and profitability.

Navidea Biopharmaceuticals has lower revenue, but higher earnings than Comera Life Sciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A
Navidea Biopharmaceuticals$8.13K0.00-$15.18M-$0.21N/A

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score.

Company Overall Sentiment
Comera Life Sciences Neutral
Navidea Biopharmaceuticals Neutral

0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. 8.9% of Comera Life Sciences shares are held by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Comera Life Sciences has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Navidea Biopharmaceuticals has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market.

Company Net Margins Return on Equity Return on Assets
Comera Life SciencesN/A N/A N/A
Navidea Biopharmaceuticals N/A N/A N/A

Summary

Navidea Biopharmaceuticals beats Comera Life Sciences on 5 of the 7 factors compared between the two stocks.

How does Comera Life Sciences compare to PaxMedica?

PaxMedica (NASDAQ:PXMD) and Comera Life Sciences (NASDAQ:CMRA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Comera Life Sciences has higher revenue and earnings than PaxMedica. PaxMedica is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PaxMedicaN/AN/A-$18.29M-$6.09N/A
Comera Life Sciences$1.00M0.00-$18M-$0.31N/A

PaxMedica has a beta of -0.99, meaning that its share price is 199% less volatile than the broader market. Comparatively, Comera Life Sciences has a beta of 1.07, meaning that its share price is 7% more volatile than the broader market.

Comera Life Sciences' return on equity of 0.00% beat PaxMedica's return on equity.

Company Net Margins Return on Equity Return on Assets
PaxMedicaN/A -3,167.89% -560.35%
Comera Life Sciences N/A N/A N/A

4.9% of PaxMedica shares are owned by institutional investors. 1.0% of PaxMedica shares are owned by company insiders. Comparatively, 8.9% of Comera Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Comera Life Sciences'average media sentiment score.

Company Overall Sentiment
PaxMedica Neutral
Comera Life Sciences Neutral

Summary

Comera Life Sciences beats PaxMedica on 7 of the 9 factors compared between the two stocks.

Get Comera Life Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for CMRA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CMRA vs. The Competition

Export
MetricComera Life SciencesPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$3K$979.54M$6.52B$12.05B
Dividend YieldN/A4.84%2.67%5.66%
P/E Ratio0.001.4524.0024.42
Price / SalesN/A120.49533.77123.88
Price / CashN/A20.0627.4837.92
Price / BookN/A7.8510.556.82
Net Income-$18M-$4.88M$3.57B$337.56M

Comera Life Sciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CMRA
Comera Life Sciences
N/AN/AN/AN/A$3K$1.00MN/A2
ARDS
Aridis Pharmaceuticals
N/A$0.00
flat		N/A+100.0%$11KN/A0.0030
TRVN
Trevena
N/A$0.00
-91.0%		N/A-99.9%$11K$443KN/A40
ADTX
Aditxt
1.0226 of 5 stars		$0.01
-2.3%		N/A-100.0%$10KN/AN/A60
NAVB
Navidea Biopharmaceuticals
N/AN/AN/AN/A$10K$8.13KN/A10

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:CMRA) was last updated on 6/15/2026 by MarketBeat.com Staff.
From Our Partners
The 1934 playbook
In 1934, a legal government maneuver transferred billions in wealth overnight. Most Americans never saw it com...
American Alternative | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Is SpaceX really worth 1.78 Trillion?
With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...
InvestPub | Sponsoredtc pixel
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel